Investor Relations - Press Releases

Investor Alerts

Nov 12, 2019

Armata Pharmaceuticals Announces Third Quarter Results and Provides Corporate and Clinical Update

Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a clinical-stage biotechnology company focused on precisely targeted bacteriophage therapeutics for...
Oct 31, 2019

Armata Pharmaceuticals Issues Letter to Shareholders

Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata"), a clinical-stage biotechnology company focused on precisely targeted bacteriophage therapeutics for antibiotic-resistant infections,...
Oct 21, 2019

Armata Pharmaceuticals Announces Receipt of $1.3 million R&D Tax Incentive

Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata"), a clinical-stage biotechnology company focused on precisely targeted bacteriophage therapeutics for antibiotic-resistant infections,...
Oct 16, 2019

Armata Pharmaceuticals Strengthens Clinical Team with Appointment of Dr. Heather Dale Jones as Medical Director

Appointment reinforces Armata's commitment to develop Pseudomonas phage product candidates

Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata"), a clinical-stage biotechnology company focused on precisely targeted bacteriophage therapeutics for antibiotic-resistant infections,...
Oct 10, 2019

Armata Pharmaceuticals Expands Board of Directors with the Appointment of Research and Development Veteran Todd C. Peterson, Ph.D.

Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata"), a clinical-stage biotechnology company focused on precisely targeted bacteriophage therapeutics for antibiotic-resistant infections,...

Show per page